# Memory Enhancement by Gamma-hydroxybutyrate vs. Trazodone in Major Depressive Disorder.

> **NCT04082806** · PHASE2 · COMPLETED · sponsor: **Erich Seifritz** · enrollment: 54 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** GHB
- **DRUG:** Trazodone
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04082806
- **Lead sponsor:** Erich Seifritz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-06
- **Primary completion:** 2022-04-06
- **Final completion:** 2022-04-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2022-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04082806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04082806, "Memory Enhancement by Gamma-hydroxybutyrate vs. Trazodone in Major Depressive Disorder.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04082806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*